Deccane Düzenci
Research Subjects
Deccane Düzenci has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Murat Bıçakcıoğlu
MALATYA TURGUT OZAL UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF SURGICAL MEDICAL SCIENCES, DEPARTMENT OF ANAESTHESIOLOGY AND REANIMATION
2 shared publications - Selçuk Demircan
Department of Reanimation Intensive Care Unit, Malatya Training and Research Hospital, Malatya, Türkiye
2 shared publications - Zeliha Korkmaz Dişli
Malatya Turgut Özal University Faculty of Medicine, Department of Anesthesiology and Reanimation, Malatya, Turkey
2 shared publications - Ahmet Bindal
Department of Anesthesiology and Reanimation, Faculty of Medicine, Suleyman Demirel University, Isparta, Türkiye
1 shared publication - Ahmet Karataş
Department of Rheumatology, Faculty of Medicine Firat University Elazig Turkey
1 shared publication - Ahmet Sait Bulut
Anesthesiology and Reanimation Intensive Care Clinic, Istanbul Medeniyet University Suleyman Yalcin City Hospital, Istanbul, Turkey
1 shared publication
Latest Publications
- 19 May 2026
- Published by Ankara Universitesi Eczacilik Fakultesi Dergisi in Ankara Universitesi Eczacilik Fakultesi Dergisi
- Vol. 50 (2) , 265-276
FACTORS AFFECTING MEROPENEM TROUGH LEVELS IN CRITICALLY ILL PATIENTS: A THERAPEUTIC DRUG MONITORING STUDY
Objective: This study primarily aimed to determine meropenem the trough level (Cmin) in intensive care unit (ICU), with an exploratory secondary aim of evaluating factors influencing Cmin and clinical cure.Material and Method: This prospective study included adult ICU patients receiving meropenem for ≥48 hours, and Cmin levels were measured using a ready-to-use ELISA kit.Result and Discussion: The study included 38 patients, 26 of whom were male. Mean meropenem Cmin value was found to be 0.40 ± 0.07 mg/l which is statistically different than the target value of 8 mg/l (p < 0.001). We found no statistically significant difference in mean Cmin between the patient groups whose creatinine clearance was smaller than 50 ml/min and not. Erythrocyte and hemoglobin values decreased after meropenem treatment compared to baseline (p < 0.05). C-Reactive Protein (CRP) decreased, and Sequential Organ Failure Assessment (SOFA) values increased after meropenem treatment (p < 0.001). Logistic regression in patients with Systemic Inflammatory Response Syndrome (SIRS) showed that only SOFA reduced the clinical cure rate (OR 0.534, 95% CI 0.311–0.917). In this study, the target 100% fT > MIC < 4×MIC was not achieved with standard or extended meropenem infusion, potentially limiting clinical cure in ICUs with resistant pathogens, highlighting the need for alternative dosing strategies.
- 19 May 2026
- Published by Ankara Universitesi Eczacilik Fakultesi Dergisi in Ankara Universitesi Eczacilik Fakultesi Dergisi
- Vol. 50 (2) , 265-276
FACTORS AFFECTING MEROPENEM TROUGH LEVELS IN CRITICALLY ILL PATIENTS: A THERAPEUTIC DRUG MONITORING STUDY
Objective: This study primarily aimed to determine meropenem the trough level (Cmin) in intensive care unit (ICU), with an exploratory secondary aim of evaluating factors influencing Cmin and clinical cure.Material and Method: This prospective study included adult ICU patients receiving meropenem for ≥48 hours, and Cmin levels were measured using a ready-to-use ELISA kit.Result and Discussion: The study included 38 patients, 26 of whom were male. Mean meropenem Cmin value was found to be 0.40 ± 0.07 mg/l which is statistically different than the target value of 8 mg/l (p < 0.001). We found no statistically significant difference in mean Cmin between the patient groups whose creatinine clearance was smaller than 50 ml/min and not. Erythrocyte and hemoglobin values decreased after meropenem treatment compared to baseline (p < 0.05). C-Reactive Protein (CRP) decreased, and Sequential Organ Failure Assessment (SOFA) values increased after meropenem treatment (p < 0.001). Logistic regression in patients with Systemic Inflammatory Response Syndrome (SIRS) showed that only SOFA reduced the clinical cure rate (OR 0.534, 95% CI 0.311–0.917). In this study, the target 100% fT > MIC < 4×MIC was not achieved with standard or extended meropenem infusion, potentially limiting clinical cure in ICUs with resistant pathogens, highlighting the need for alternative dosing strategies.
- 24 January 2025
- Published by Academician Publishing
- p. 21-28
Crush Sendromlu Olguya Yaklaşım
Maraş merkezli depremde göçük altında kalan 17 yaşında 110 kilogram ağırlığında hasta göçük altından çıkarılıp; acil serviste üst extremite ve alt extremitede çoklu kırıklar ile sağ pnömotorax tanıları konularak göğüs tüpü takılı olarak yoğum bakım servisimize kabul edildi. Kliniğimize gelişinde kreatinin kinaz (CK), miyoglobin, karaciğer enzim yüksekliği ve potasyum yüksekliği olan olgu kompartman sendromu olmaması nedeniyle cerrahi işlem yapılmayıp acil diyalize alındı. Yatışının 3. gününde CK, miyoglobin değerleri kompartman sendromu gelişmemesine ve diyaliz tedavisinin yapılmasına rağmen CK değeri düşmeyen, anürik olup metabolik asidozu derinleşip Glaskow Koma Skoru gerileyen olgu elektif entübe edilerek sağ üst extremiteye dirsek üstü ampütasyon yapıldı. Yatışının 23. günü solunum parametreleri ve böbrek fonksiyonları normale dönmesi üzerine extübe edilerek; CVVHD tedavisi sonlandırıldı. 30. günde böbrek fonksiyonları normale dönen, kliniği düzelen ve solunum parametreleri normal seyreden hasta servise devredildi. The 17-year-old patient weighing 110 kg was rescued from under the collapse in the Maraş earthquake and diagnosed with multiple fractures in the upper and lower extremities and right pneumothorax in the emergency department and admitted to our intensive care unit with a chest tube. The patient who had elevated creatinine kinase (CK), myoglobin, liver enzymes and potassium at the time of admission to our clinic was put on urgent dialysis without surgical procedure because of the absence of compartment syndrome. On the 3rd day of hospitalisation, CK and myoglobin levels did not decrease despite the absence of compartment syndrome and dialysis treatment, the patient became anuric and metabolic acidosis deepened. The patient was intubated and above elbow amputation of the right upper extremity was performed. On the 23rd day of hospitalisation, respiratory parameters and renal functions returned to normal, the patient was intubated and CVVHD treatment was terminated. On the 30th day, the patient was transferred to the ward with improved renal function, improved clinic and normal respiratory parameters.
- 24 January 2025
- Published by Academician Publishing
- p. 21-28
Crush Sendromlu Olguya Yaklaşım
Maraş merkezli depremde göçük altında kalan 17 yaşında 110 kilogram ağırlığında hasta göçük altından çıkarılıp; acil serviste üst extremite ve alt extremitede çoklu kırıklar ile sağ pnömotorax tanıları konularak göğüs tüpü takılı olarak yoğum bakım servisimize kabul edildi. Kliniğimize gelişinde kreatinin kinaz (CK), miyoglobin, karaciğer enzim yüksekliği ve potasyum yüksekliği olan olgu kompartman sendromu olmaması nedeniyle cerrahi işlem yapılmayıp acil diyalize alındı. Yatışının 3. gününde CK, miyoglobin değerleri kompartman sendromu gelişmemesine ve diyaliz tedavisinin yapılmasına rağmen CK değeri düşmeyen, anürik olup metabolik asidozu derinleşip Glaskow Koma Skoru gerileyen olgu elektif entübe edilerek sağ üst extremiteye dirsek üstü ampütasyon yapıldı. Yatışının 23. günü solunum parametreleri ve böbrek fonksiyonları normale dönmesi üzerine extübe edilerek; CVVHD tedavisi sonlandırıldı. 30. günde böbrek fonksiyonları normale dönen, kliniği düzelen ve solunum parametreleri normal seyreden hasta servise devredildi. The 17-year-old patient weighing 110 kg was rescued from under the collapse in the Maraş earthquake and diagnosed with multiple fractures in the upper and lower extremities and right pneumothorax in the emergency department and admitted to our intensive care unit with a chest tube. The patient who had elevated creatinine kinase (CK), myoglobin, liver enzymes and potassium at the time of admission to our clinic was put on urgent dialysis without surgical procedure because of the absence of compartment syndrome. On the 3rd day of hospitalisation, CK and myoglobin levels did not decrease despite the absence of compartment syndrome and dialysis treatment, the patient became anuric and metabolic acidosis deepened. The patient was intubated and above elbow amputation of the right upper extremity was performed. On the 23rd day of hospitalisation, respiratory parameters and renal functions returned to normal, the patient was intubated and CVVHD treatment was terminated. On the 30th day, the patient was transferred to the ward with improved renal function, improved clinic and normal respiratory parameters.
- 24 January 2025
- Published by Academician Publishing
Olgularla Yoğun Bakım
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1) , 9096871
Clinical and Histopathological Correlation of Quantitative HBsAg Levels in Chronic Hepatitis B
Objective: This study is aimed at comparing different clinical forms of chronic hepatitis B (CHB) infection (HBeAg‐negative chronic HBV infection and HBeAg‐positive and HBeAg‐negative CHB patients) and evaluate their demographic, laboratory, virological, and histopathological characteristics, as well as investigate the relationship between quantitative HBsAg (qHBsAg) levels and these parameters. Materials and Methods: This prospective study included a total of 307 patients, comprising 142 HBeAg‐negative chronic HBV infection and 165 CHB patients (39 HBeAg‐positive and 126 HBeAg‐negative). Patient data, including age, sex, ALT, AST, GGT, ALP, total bilirubin, HBV DNA, and qHBsAg levels, were recorded. Additionally, liver biopsy was performed in 111 cases (31 HBeAg‐positive and 80 HBeAg‐negative), and histological activity index (HAI) and fibrosis staging (ISHAK score) were evaluated. Results: No significant differences were observed between HBeAg‐negative chronic HBV infection and CHB patients in age and sex distribution. In the CHB group, ALT and HBV DNA levels were significantly higher ( p = 0.014 and p = 0.025, respectively). Among CHB patients, HBeAg‐positive patients had significantly lower qHBsAg levels than HBeAg‐negative patients (1805 vs. 4028 IU/mL, p < 0.001). Histopathological evaluations showed no significant association between qHBsAg levels and fibrosis severity (ISHAK score > 2) or necroinflammatory activity (HAI > 6). ROC analysis confirmed the limited diagnostic value of qHBsAg for advanced fibrosis (AUC 0.511, 95% CI 0.454–0.569). In HBeAg‐positive patients, a weak negative correlation was found between qHBsAg and HBV DNA levels ( r = –0.388, p = 0.015). Discussion: Our study demonstrated variability in laboratory findings across different forms of CHB. Notably, HBeAg‐positive patients exhibited high HBV DNA levels alongside low qHBsAg levels. The limited efficacy of qHBsAg as a fibrosis marker suggests caution in its clinical use. These findings underscore the importance of considering multiple parameters in assessing liver damage.
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1) , 9096871
Open AccessClinical and Histopathological Correlation of Quantitative HBsAg Levels in Chronic Hepatitis B
Objective: This study is aimed at comparing different clinical forms of chronic hepatitis B (CHB) infection (HBeAg‐negative chronic HBV infection and HBeAg‐positive and HBeAg‐negative CHB patients) and evaluate their demographic, laboratory, virological, and histopathological characteristics, as well as investigate the relationship between quantitative HBsAg (qHBsAg) levels and these parameters. Materials and Methods: This prospective study included a total of 307 patients, comprising 142 HBeAg‐negative chronic HBV infection and 165 CHB patients (39 HBeAg‐positive and 126 HBeAg‐negative). Patient data, including age, sex, ALT, AST, GGT, ALP, total bilirubin, HBV DNA, and qHBsAg levels, were recorded. Additionally, liver biopsy was performed in 111 cases (31 HBeAg‐positive and 80 HBeAg‐negative), and histological activity index (HAI) and fibrosis staging (ISHAK score) were evaluated. Results: No significant differences were observed between HBeAg‐negative chronic HBV infection and CHB patients in age and sex distribution. In the CHB group, ALT and HBV DNA levels were significantly higher ( p = 0.014 and p = 0.025, respectively). Among CHB patients, HBeAg‐positive patients had significantly lower qHBsAg levels than HBeAg‐negative patients (1805 vs. 4028 IU/mL, p < 0.001). Histopathological evaluations showed no significant association between qHBsAg levels and fibrosis severity (ISHAK score > 2) or necroinflammatory activity (HAI > 6). ROC analysis confirmed the limited diagnostic value of qHBsAg for advanced fibrosis (AUC 0.511, 95% CI 0.454–0.569). In HBeAg‐positive patients, a weak negative correlation was found between qHBsAg and HBV DNA levels ( r = –0.388, p = 0.015). Discussion: Our study demonstrated variability in laboratory findings across different forms of CHB. Notably, HBeAg‐positive patients exhibited high HBV DNA levels alongside low qHBsAg levels. The limited efficacy of qHBsAg as a fibrosis marker suggests caution in its clinical use. These findings underscore the importance of considering multiple parameters in assessing liver damage.
- 1 December 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (12) , 865-870
Comparison of tocilizumab and intravenous immunoglobulin treatment in intensive care unit patients with covid-19 who developed cytokine storm: a single-center retrospective study
Aim Coronavirus disease 2019 (COVID-19) may trigger a severe inflammatory response. In the present study, the effects of tocilizumab and intravenous immunoglobulin (IVIG) on mortality in COVID-19 patients with cytokine storms were examined and compared. Methods This retrospective study included all COVID-19 patients who were diagnosed and followed in the intensive care unit between April 2020 and May 2022. The patients were divided into two groups depending on whether they were receiving IVIG or tocilizumab treatment. In addition to the patients’ demographic information, the 28-day mortality was recorded. Their PaO2/FiO2 ratio, CRP, procalcitonin, lymphocyte, ferritin, and D-dimer levels were also recorded before drug administration and on the first day, third day, and first week following the drug administration. Results Of the 73 patients included in this study, 43 (59%) received tocilizumab (Group T), while 30 (41%) received IVIG treatment (Group IVIG). No significant statistical differences were detected between the groups in terms of demographic data, pre-drug inflammatory parameters, improvement in PaO2/FiO2 ratios, and 28-day mortality. The rate of change in CRP levels was significantly higher in Group T than in Group IVIG on day 3 (P = .010) and in the first week (P = .001). The improvement in ferritin levels in the first week was significantly higher in Group T (P = .018). Conclusion No significant difference was detected between the effects of IVIG and tocilizumab on mortality in COVID-19 patients with cytokine storm. However, tocilizumab suppressed inflammation more strongly than IVIG.
- 1 December 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (12) , 865-870
Comparison of tocilizumab and intravenous immunoglobulin treatment in intensive care unit patients with covid-19 who developed cytokine storm: a single-center retrospective study
Aim Coronavirus disease 2019 (COVID-19) may trigger a severe inflammatory response. In the present study, the effects of tocilizumab and intravenous immunoglobulin (IVIG) on mortality in COVID-19 patients with cytokine storms were examined and compared. Methods This retrospective study included all COVID-19 patients who were diagnosed and followed in the intensive care unit between April 2020 and May 2022. The patients were divided into two groups depending on whether they were receiving IVIG or tocilizumab treatment. In addition to the patients’ demographic information, the 28-day mortality was recorded. Their PaO2/FiO2 ratio, CRP, procalcitonin, lymphocyte, ferritin, and D-dimer levels were also recorded before drug administration and on the first day, third day, and first week following the drug administration. Results Of the 73 patients included in this study, 43 (59%) received tocilizumab (Group T), while 30 (41%) received IVIG treatment (Group IVIG). No significant statistical differences were detected between the groups in terms of demographic data, pre-drug inflammatory parameters, improvement in PaO2/FiO2 ratios, and 28-day mortality. The rate of change in CRP levels was significantly higher in Group T than in Group IVIG on day 3 (P = .010) and in the first week (P = .001). The improvement in ferritin levels in the first week was significantly higher in Group T (P = .018). Conclusion No significant difference was detected between the effects of IVIG and tocilizumab on mortality in COVID-19 patients with cytokine storm. However, tocilizumab suppressed inflammation more strongly than IVIG.
- 31 October 2024
- Published by Caleo in Rheumatology Quarterly
- Vol. 2 (3) , 137-143
A THROMBOSPONDIN TYPE-1 MOTIF, MEMBER 13 (ADAMTS13) LEVELS DECREASE IN COVID-19 PATIENTS
Aim:Thrombotic pathologies develop at an increasing rate in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Understanding the pathologies that cause thrombosis in SARS-CoV-2 infection is important for developing prophylaxis strategies for the development of thrombosis and regulating treatment in cases of thrombosis. For all these reasons, we aimed to evaluate the levels of A disintegrin and metalloproteinase with a Thrombospondin Type-1 Motif Member 13 (ADAMTS13), in SARS-CoV-2 patients. Material and Methods:The data of patients who were followed up in the intensive care unit due to coronavirus disease of 2019 (COVID-19) with lung involvement, who received respiratory support and pulse steroid therapy, and those who were followed up as outpatients without lung involvement were analyzed. Demographic data, laboratory results, and serum ADAMTS13 levels were recorded. These results were compared with those of the control group. Results:ADAMTS13 levels were significantly lower in the COVID-19 group without lung involvement than in the control group (p=0.037). ADAMTS13 levels were significantly lower in the COVID-19 group with lung involvement than in the control group (p=0.016). There was no difference in ADAMTS13 levels between COVID-19 patients with and without lung involvement (p=0.797). There was no significant difference in ADAMTS13 levels between patients with and without chronic diseases in the COVID-19 group (p=0.40 for those without lung involvement; p=0.573 for those with lung involvement). Conclusion:SARS-CoV-2 caused a decrease in ADAMTS13 levels. ADAMTS13 levels were decreased more in patients with lung involvement than in those without lung involvement. Decreased ADAMTS13 levels in COVID-19 may be a cause of the prothrombotic process.
- 31 October 2024
- Published by Caleo in Rheumatology Quarterly
- Vol. 2 (3) , 137-143
A THROMBOSPONDIN TYPE-1 MOTIF, MEMBER 13 (ADAMTS13) LEVELS DECREASE IN COVID-19 PATIENTS
Aim:Thrombotic pathologies develop at an increasing rate in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Understanding the pathologies that cause thrombosis in SARS-CoV-2 infection is important for developing prophylaxis strategies for the development of thrombosis and regulating treatment in cases of thrombosis. For all these reasons, we aimed to evaluate the levels of A disintegrin and metalloproteinase with a Thrombospondin Type-1 Motif Member 13 (ADAMTS13), in SARS-CoV-2 patients. Material and Methods:The data of patients who were followed up in the intensive care unit due to coronavirus disease of 2019 (COVID-19) with lung involvement, who received respiratory support and pulse steroid therapy, and those who were followed up as outpatients without lung involvement were analyzed. Demographic data, laboratory results, and serum ADAMTS13 levels were recorded. These results were compared with those of the control group. Results:ADAMTS13 levels were significantly lower in the COVID-19 group without lung involvement than in the control group (p=0.037). ADAMTS13 levels were significantly lower in the COVID-19 group with lung involvement than in the control group (p=0.016). There was no difference in ADAMTS13 levels between COVID-19 patients with and without lung involvement (p=0.797). There was no significant difference in ADAMTS13 levels between patients with and without chronic diseases in the COVID-19 group (p=0.40 for those without lung involvement; p=0.573 for those with lung involvement). Conclusion:SARS-CoV-2 caused a decrease in ADAMTS13 levels. ADAMTS13 levels were decreased more in patients with lung involvement than in those without lung involvement. Decreased ADAMTS13 levels in COVID-19 may be a cause of the prothrombotic process.